Joint Involvement And Aggressive Systemic Sclerosis PDF Print E-mail
Thursday, 16 September 2010 08:46
Clinical joint involvement is strikingly common in patients with systemic sclerosis (scleroderma) and is associated with a more active and severe disease phenotype, according to an analysis of the world’s largest systemic sclerosis (SSc) registry.

Synovitis proved to have a particularly strong association with systemic inflammation in this study. However, Synovitis often occurred in concert with joint contractures and/or tendon friction rubs, raising the possibility of a shared underlying mechanism in their development , Dr. Jérôme Avouac said at the annual European Congress of Rheumatology.

He presented an analysis of joint symptoms and their clinical implications in 7,286 patients with systemic sclerosis (SSc) enrolled in the EULAR Scleroderma Trials and Research (EUSTAR) registry, the world’s largest SSc database. Of registrants, 58% had the limited cutaneous subtype of SSc, 33% had the diffuse cutaneous subtype, and 9% were not classified.

Synovitis, joint contractures, and tendon friction rubs more prevalent in patients with the diffuse cutaneous subtype noted Dr. Avouac of Cochin Hospital, Paris.

Active disease, as defined by the 17-point dermal ultrasound, modified Rodnan skin scoring system, was present in 29% of the overall study population. Synovitis was associated with a highly significant 70% increased likelihood of having active disease, while tendon friction rubs were associated with a 51% increased rate. In contrast, joint contractures had no impact upon the risk of having active disease.

Synovitis was also associated with a 47% increased likelihood of having muscle weakness, a 49% increase in the risk of having elevated systolic pulmonary artery pressure, a 49% increase in the odds of having elevation of acute phase reactants, and a 29% increase in anti-topoisomerase-1 antibody positivity.

Patients with joint contractures were significantly more likely to have digital ulcerations (93% increased risk), elevated systolic pulmonary artery pressure (38% increased risk), muscle weakness (41% increase), and pulmonary fibrosis (23% increased risk), the rheumatologist continued.

Tendon friction rubs were associated with a 21% increased likelihood of experiencing digital ulceration, a 22% increase in pulmonary fibrosis, and a 38% greater likelihood of proteinuria.

These study findings provide support for making early detection of articular involvement in SSc a disease-management priority, according to Dr. Avouac.

He noted, however, that this was a cross-sectional analysis. Ongoing prospective follow-up of the EUSTAR registry participants will enable investigators to make a definitive determination of the merits of articular involvement as a predictor of disease severity

Source: Jancin, B (2010), "Joint Involvement Predicts Aggressive Systemic Sclerosis", Skin and Allergy News, viewed online at http://bit.ly/dxrK4J
 
More articles :

» Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis

Marco Matucci-Cerinic, Christopher P Denton, Daniel E Furst, Maureen D Mayes, Vivien M Hsu, Patrick Carpentier, Fredrick M Wigley, Carol M Black, Barri J Fessler, Peter A Merkel, Janet E Pope, Nadera J Sweiss, Mittie K Doyle, Bernhard Hellmich,...

» Scleroderma Foundation's 13th Annual National Patient Education Conference Is Here

Nearly 600 people are anticipated to visit the heart of San Francisco Friday, July 8, through Sunday, July 10, for the Scleroderma Foundation's 13th Annual National Patient Education Conference. Patients, family members, caregivers, doctors and...

» Real-World Bosentan Therapy Successful in Pulmonary Arterial Hypertension: Presented at ATS

Real-life experiences in treating patients with pulmonary arterial hypertension with bosentan appears to provide similar efficacy as seen in clinical trials -- despite patients being somewhat older and having more scleroderma, researchers said today...

» Facing Life's Challenges

At 57 years of age Anne Wersching doesn’t have a single wrinkle on her face.Sitting in her lounge room in Bayswater North, Ms Wersching looks well, save for a few red marks on her cheeks.But Ms Wersching has a little-known disease called...

» Actelion Announces FDA Approval of Brand Name, Veletri, for Pulmonary Arterial Hypertension

US, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for...

» A New Marker of Silent Cardiovascular Disease in Diffuse Scleroderma

Patients with diffuse systemic sclerosis (SSc) and no clinical evidence of (CVD) may, in fact, have subclinical CVD and , and it is detectable. This is the conclusion of a small pilot study from Italy, which showed that elevated plasma levels of ...

Add comment

Do feel free to leave your comments, as they would add value and knowledge to the community. However, please refrain from making any disparaging, uninformed, or unrelated comments. Thanks :)

Security code
Refresh